EQRx's Aumolertinib May Be A Serious Competitive Contender For Tagrisso

The price of aumolertinib will be "radically lower" than what has become commonplace for cancer medicines, president Melanie Nallicheri told Scrip.

Storm clouds — A new competitive threat is brewing for Tagrisso • Source: Alamy

EQRx, Inc. has its eye on the lung cancer market dominated by AstraZeneca PLC's blockbuster Tagrisso (osimertinib) and appears one step closer to launching its lower-priced rival aumolertinib. The relative newcomer, with its partner, Hansoh Pharmaceutical Group Company Limited, disclosed positive Phase III study results for the epidermal growth factor receptor (EGFR) inhibitor aumolertinib in first-line advanced or metastatic non-small cell lung cancer (NSCLC) on 19 May.

Detailed data will appear in a poster presentation at the American Society of Clinical Oncology virtual meeting on 4 June.